AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its ...

AstraZeneca (AZ) has shared positive results from a phase 3b study of its anti-inflammatory reliever rescue therapy Airsupra ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

The BATURA trial compared the use of Airsupra to albuterol, a commonly used rescue medicine in the US. The trial showed that ...

The results from the AIRSUPRA BATURA trial add to a wide body of evidence on the value of the anti-inflammatory reliever rescue approach to not only provide immediate relief from symptoms ...

The trial has shown that Airsupra, AstraZeneca’s anti-inflammatory reliever rescue therapy, has demonstrated substantial improvements in treating patients with mild asthma. The results of the ...

Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, ...